ArticleScience progress
Inflammation-metabolite crosstalk in multiple sclerosis: A mediation Mendelian randomization study of plasma inflammatory proteins, iron, and serum/cerebrospinal fluid metabolites.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the causal relationships between inflammatory proteins, iron metabolism, blood/CSF metabolites, and multiple sclerosis (MS) risk using genetic evidence.MethodsWe performed a two-sample, two-step Mendelian randomization (MR) analysis using European-ancestry genome-wide association study data. The exposures comprised 91 inflammatory proteins, while potential mediators included 1091 blood metabolites, 309 metabolite ratios, 233 circulating metabolic traits, and 338 cerebrospinal fluid metabolites. For the outcome, we assessed MS risk using two independent datasets: International Multiple Sclerosis Genetics Consortium (IMSGC) and UK Biobank. Our primary analysis utilized inverse-variance weighted regression. To ensure robust results, we conducted comprehensive sensitivity analyses including MR-Egger, weighted median, MR-PRESSO, and Bayesian Weighted MR approaches to evaluate potential pleiotropy and strengthen causal inference.ResultsWe observed a statistically significant but modest elevation in MS risk associated with interleukin-7 (IL-7; OR = 1.40, 95% CI: 1.07-1.83,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.